Side by side
How the two compare across structure, mechanism studied, evidence and regulatory status, based on published research.
| Property | Selank | Semax |
|---|---|---|
| Class | Experimental anxiolytic neuropeptide | Experimental nootropic neuropeptide |
| Research category | anxiety and cognition models | cognition and neuroprotection |
| Evidence level | Low | Low |
| Overall status | Not approved — research (registered in Russia only) | Not approved — research (registered in Russia only) |
| FDA | Not approved | Not approved |
| EMA | Not approved | Not approved |
| WADA | Check current list | Check current list |
| Mechanism studied | Selank → CNS (intranasal models) → GABA / serotonin modulation → Behavioural endpoints | Semax → CNS (intranasal models) → BDNF / TrkB → Neuroprotection models |
| Molecular weight | 751.9 g/mol | 813.9 g/mol |
| Sizes in stock | 5mg, 10mg | 5mg, 10mg |
Where the research overlaps
Both compounds are studied within Cognitive & Neuro research. Selank is classed as experimental anxiolytic neuropeptide, while Semax is experimental nootropic neuropeptide. Evidence is rated low for Selank and low for Semax.
For a full write-up, read Selank and Semax: A Research Review.
FOR RESEARCH USE ONLY.Not for human or veterinary use. Not intended to diagnose, treat, cure, or prevent any disease.